

Jefferies 2014 Global Healthcare Conference, New York

June 2014

Disclaimer



This presentation has been organised by Vectura Group plc (the Company) in order to provide general information on the Company. This material has been prepared solely by the Company and is (i) for your private information, and the Company is not soliciting any action based upon it (ii) not to be construed as an offer to sell or issue or a solicitation of an offer to buy or subscribe for any security and (iii) based upon information that the Company considers reliable. The Company does not represent that the information contained in this material is accurate or complete, and it should not be relied upon as such. No representation, warranty or undertaking, express or implied, is or will be made with respect to the fairness, accuracy or completeness of any of the information or statement of opinion or expectation contained herein or stated in the presentation or any other such information nor shall you be entitled to rely upon it. In furnishing you with this information no obligation is undertaken to provide you with any further information, to update this information nor any other information nor to correct any information contained herein or any omission therefrom.

The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Act"), and may not be offered or sold in the United States or to U.S. persons unless they have been registered under such Act, or except in compliance with an exemption from or in a transaction not subject to the registration requirements of such Act.

This presentation has not been approved or disapproved by the US Securities and Exchange Commission, any state securities commission in the United States or any other regulatory authority in the United States, nor have any of the foregoing authorities passed on the accuracy or adequacy of the information contained in this material. Any representation to the contrary is a criminal offence in the United States.

This material does constitute or form part of any offer or invitation to sell or issue or any solicitation of an offer to acquire, purchase or subscribe for the Company's securities in any jurisdiction.


No part of this material may be (i) copied, photocopied, or duplicated in any form, by any means, or (ii) redistributed, published, or disclosed by recipients to any other person, in each case without the Company's prior written consent. This material is only being provided to persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 or any order made thereunder or to other persons of a kind described in Articles 19 and 49 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, who are "qualified institutional buyers" as defined in Rule 144 under the Act or institutional "accredited investors" as defined in Rule 501 of Regulation D under the Act, or who are otherwise permitted by law to receive it.

In relation to information about the price at which securities in the Company have been bought or sold in the past, note that past performance cannot be relied upon as a guide to future performance. In addition, certain statements, beliefs and opinions in this document, are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. The occurrence of some of the events described in this document and the presentation that will be made, and the achievement of the intended results, are subject to the future occurrence of many events, some or all of which are not predictable or within the Company's control; therefore, actual results may differ materially from those anticipated in any forward looking statements. The Company disclaims any obligation to update these forward looking statements.

By attending the presentation to which this document relates or by accepting this document you will be taken to have represented, warranted and undertaken that: (i) you are a person falling within one or more of the categories referred to above as being permitted to receive this presentation (ii) you have read and agree to comply with the contents of this disclaimer notice; and (iii) you will not at any time have any discussion, correspondence or contact concerning the information in this document with any of the directors or employees of the Company, its subsidiaries nor with any of their suppliers, customers, sub contractors or any governmental or regulatory body without the prior written consent of the Company.


Vision

Building a speciality pharma business focussed on
airways disease



Identifying our focus

To build a sustainable business




The size of the bubbles does not reflect the relative market size of the indications shown.

All information and imagery © Vectura Group plc

*Note: The vertical axis, quantifying unmet need, is based on scientific and clinical reviews of the disease area combined with the views of the Directors.

Identifying areas of potential interest

 Currently partnered  Areas of current and future interest



*Note: The vertical axis, quantifying unmet need, is based on scientific and clinical reviews of the disease area combined with the views of the Directors. Abbreviations used: IPF Idiopathic Pulmonary Fibrosis; AAT Alpha Anti-Trypsin; PAH Pulmonary Arterial Hypertension; RSV Respiratory Syncytial Virus.

In-market, revenue-generating assets



Building a growing, diversified revenue stream

- ✓ Additional revenue streams build on Baxter royalties
- ✓ Seebri® Breezhaler® approved in more than 60 countries, EU, Canada, Australia and Japan¹
 - Market roll out is underway by Novartis; net sales \$30m in Q1, 14 (\$58m FY2013)
 - Filing for asthma indication expected 2016
 - US filing expected Q4, 2014
- ✓ Ultibro® Breezhaler® approved in more than 30 countries EU, Canada, Australia and Japan²
 - Positioned to establish a new standard of care in COPD; net sales \$14m in Q1, 14
 - Launched in seven countries to date with 30+ countries expected in 2014
 - US filing expected Q4, 2014
- ✓ AirFluSal® Forspiro® approved in Europe and S. Korea
- ✓ GSK: BREO™ ELLIPTA™ & ANORO™ ELLIPTA™

¹Seebri® Inhalation Capsules in Japan ²Ultibro® Inhalation Capsules in Japan
Seebri® Breezhaler® & Ultibro® Breezhaler® are registered trademarks of Novartis AG

At the forefront of inhaled generic products



- ✔ US regulatory landscape has changed
 - Facilitating approval of generic inhaled products
- ✔ Competition is limited to companies that possess the appropriate mix of technical and development capabilities
 - Vectura has the capability to deliver generic inhaled products
- ✔ Vectura and partners are well positioned to play a significant role globally
 - AirFluSal[®] Forspiro[®] approved in some EU and ROW countries
 - Recent development milestone attained for VR315 US – good progress
 - Confidence for further product opportunities VR632 and VR506
- ✔ Limited competition maintains a high potential value

Pipeline



VR588

Severe Inflammatory
Airway Disease
(Global)

VR611

Airways Inflammation
& Chronic Cough
(Global)

VR942 (UCB)

Inflammatory
Airway disease
(Co development global)

VR475

Severe Adult
Asthma
(US)

VR465 (Ablynx)

RSV Infection
(Global)

VR647

Paediatric Asthma
(Global)

VR179 (Grifols)

Cystic Fibrosis
(Global)

VR736 (Ventaleon)

Severe Influenza
(Global)

SB010 (sterna biologicals)

Asthma & other
respiratory diseases
(Global)

NVA237 (Novartis)

COPD
(US)

QVA149 (Novartis)

COPD
(US)

VR475

Severe Adult Asthma
(EU)

VR876 (partnered, undisclosed)

Pulmonary
Hypertension
(Global)

Generic assets

VR315 (partnered, undisclosed)

Asthma
(US)

VR506

Asthma
(US)

VR632 (Sandoz)

Asthma
(EU)



Pre clinical

Phase 1

Phase 2

Phase 3

Full
development

Filed


Product value proposition

Underpinned by our technologies




✔ Lactose blend formulations e.g. AirFluSal[®] Forspiro[®]

✔ PowderHale[®] technology e.g. Ultibro[®] & Seebri[®]



Fine Particle Mass on Stability
Molecule A



✔ Improved small molecule products with PowderMax[™]

✔ Preserving biological activity with ParticleMax[™]

Devices

Delivering our products in a patient-focussed manner



Clickhaler

- Reservoir multi-dose
- Focus on Emerging Markets
- Kinnovata



Gyrohaler

- Multi-dose DPI range



Platform evolution


- Lever operated
 - In development
- Open-inhale-close
 - Potential future development

Application across branded and generic drugs, small molecules and biologics


Smart inhalation technology...




FAVORITE: Flow And Volume Regulated Inhalation TEchnology



Tidal Breathing
(typical short and abrupt
inhalation pattern)



FAVORITE Inhalation
(slow and deep inhalation)



- FAVORITE goes beyond getting the drug into the lung, by pre-targeting desired deposition area and enabling more efficient drug utilisation

...with devices that deliver patient benefits



AKITA® JET nebuliser

- Approved (CE Mark /510k) and is being sold in Germany and other EU territories
- Used with a smart card for FAVOLIR®



APIXNEB

- Mesh nebuliser in system; Approved (CE Mark /510k)
- Higher nebulisation efficiency



FOX inhalation system

- Hand held battery driven nebuliser with high performance. Re-chargeable and bluetooth enabled
- CE mark

- ✔ Tailored to individual's breathing capacity
- ✔ Highly consistent and reproducible dosing
- ✔ Improved efficiency of delivery
 - Lower dose of drug required to deliver therapeutic effect
 - Potential for reduced side-effect profile
 - Shorter inhalation times

Financial Highlights

Financial highlights



£m	FY 2013/14	FY 2012/13
Revenue	36.5	30.5
Gross profit	35.5	29.8
EBITDA	5.2	(3.4)
Loss before tax	(4.8)	(10.4)
Cash	81.7	70.1

Positive EBITDA
£5.2m

(FY:2012/13 - £3.4m loss)

Strong balance sheet with cash
of £81.7m

(FY:2012/13 - £70.1m)

Outlook

Upcoming events



Progress of Seebri[®] Breezhaler[®] reported quarterly

- US filing anticipated in H2, 2014

Ultibro[®] Breezhaler[®] launch underway in Japan & Europe

- First in class of major new drug class
- US filing anticipated in H2, 2014

AirFluSal[®] Forspiro[®] (VR315)

- Approved in parts of EU and RoW
- Launch roll-out underway

VR475 (FAVOLIR[®]) update

- Initiation of EU Ph III clinical study H2, 2014
- Initiation of US development programme H2, 2014

VR647 (SCIPE)

- Initiation of development programme in EU and US H2, 2014

Thank you.....